Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Area of Science:

• Oncology
• Dermatology
• Medical Guidelines

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with unique risk factors and treatment challenges.
• Emerging data necessitates updates to clinical practice guidelines for optimal patient management.

Purpose of the Study:

• To summarize recent updates to the NCCN Guidelines for MCC based on new evidence.
• To highlight changes in risk factor assessment, diagnostic workup, and management of advanced or metastatic MCC.

Main Methods:

• Review of recently published data and its incorporation into the NCCN Guidelines for MCC.
• Focus on updated recommendations for diagnostic biomarkers and systemic therapies.

Main Results:

• Incorporation of Merkel cell polyomavirus (MCPyV) as a biomarker in MCC diagnosis and risk stratification.
• New recommendations for the use of checkpoint immunotherapies in metastatic or unresectable MCC.
• Updated guidance on risk factors, diagnosis, workup, follow-up, and management of advanced MCC.

Conclusions:

• The updated NCCN Guidelines provide crucial information on utilizing MCPyV biomarkers and checkpoint immunotherapies for MCC.
• These revisions reflect advancements in understanding and treating advanced Merkel cell carcinoma, improving patient care pathways.